DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils.

Author(s): Chaudhuri R(1), Norris V(2), Kelly K(3), Zhu CQ(4), Ambery C(5), Lafferty J(6), Cameron E(6), Thomson NC(6).

Affiliation(s): Author information: (1)Institute of Infection, Immunity & Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK. Electronic address: Rekha.Chaudhuri@ggc.scot.nhs.uk. (2)Immuno-Inflammation Therapy Area, GlaxoSmithKline, Stevenage, UK. (3)Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, UK. (4)Clinical Statistics, GlaxoSmithKline, Uxbridge, UK. (5)Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Uxbridge, UK. (6)Institute of Infection, Immunity & Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK.

Publication date & source: 2014, Pulm Pharmacol Ther. , 27(1):62-9

Patients with refractory asthma frequently have neutrophilic airway inflammation and respond poorly to inhaled corticosteroids. This study evaluated the effects of an oral 5-lipoxygenase-activating protein (FLAP) inhibitor, GSK2190915, in patients with asthma and elevated sputum neutrophils. Patients received 14 (range 13-16) days treatment with GSK2190915 100 mg and placebo with a minimum 14 day washout in a double-blind, cross-over, randomised design (N = 14). Sputum induction was performed twice pre-dose in each treatment period to confirm sputum neutrophilia, and twice at the end of each treatment period. The primary endpoint was the percentage and absolute sputum neutrophil count, averaged for end-of-treatment visits. GSK2190915 did not significantly reduce mean percentage sputum neutrophils (GSK2190915-placebo difference [95% CI]: -0.9 [-12.0, 10.3]), or mean sputum neutrophil counts (GSK2190915/placebo ratio [95% CI]: 1.06 [0.43, 2.61]). GSK2190915 resulted in a marked suppression (>90%) of sputum LTB4 and urine LTE4, but did not alter clinical endpoints. There were no safety issues. Despite suppressing the target mediator LTB4, FLAP inhibitor GSK2190915 had no short-term effect on sputum cell counts or clinical endpoints in patients with asthma and sputum neutrophilia.

Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017